RxDoctor Payments Data

Colleen Dougherty

Family · Jermyn, PANPI 1609392117

Payments from drug & device makers

$1,050in general payments, 2019–2025

Across 47 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$297
  • AbbVie$121
  • Lilly USA, LLC$106
  • Pfizer$93
  • Gilead$57
  • Indivior Inc.$54
  • plus $322 from 14 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,050 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,329
Medicare patients
37
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$21,729
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$1,431
Rosuvastatin Calcium62$1,154
Albuterol Sulfate HfaAlbuterol Sulfate20$1,028
FenofibrateFenofibrate Nanocrystallized19$800
Levothyroxine Sodium63$721
Sucralfate11$582
Pantoprazole Sodium37$574
Atorvastatin Calcium32$540
Cephalexin15$359
Metformin Hcl20$301
Gabapentin21$300
Amlodipine Besylate51$297
Metoprolol Succinate46$291
Clonidine Hcl15$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$21,72924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Jermyn

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →